Das Universitätsklinikum Erlangen ist ein Klinikum der Maximalversorgungsstufe und das Klinikum der medizinischen Fakultät der Friedrich-Alexander-Universität Erlangen-Nürnberg. Es ist neben dem Waldkrankenhaus St.

During the past decade, Universitätsklinikum Erlangen conducted 213 clinical trials. In the 10-year time frame, 213 clinical trials started and 72 clinical trials were completed, i.e. on average, 33.8% percent of trials that started reached the finish line to date. In the past 5 years, 89 clinical trials started and 57 clinical trials were completed. i.e. 64% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Universitätsklinikum Erlangen" #1 sponsor was "University of Erlangen-Nürnberg Medical School" with 35 trials, followed by "Boehringer Ingelheim" with 19 trials sponsored, "Janssen Research & Development, LLC" with 9 trials sponsored, "Pfizer" with 9 trials sponsored and "Eli Lilly and Company" with 9 trials sponsored. Other sponsors include 233 different institutions and companies that sponsored additional 169 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Universitätsklinikum Erlangen" #1 collaborator was "University Hospital Erlangen" with 6 trials as a collaborator, "AstraZeneca" with 4 trials as a collaborator, "Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK)" with 4 trials as a collaborator, "Hannover Medical School" with 4 trials as a collaborator and "Merck Sharp & Dohme LLC" with 4 trials as a collaborator. Other collaborators include 262 different institutions and companies that were collaborators in the rest 231 trials.

According to Clinical.Site data, the most researched conditions in "Universitätsklinikum Erlangen" are "Coronary Artery Disease" (15 trials), "Heart Failure" (9 trials), "Breast Cancer" (8 trials), "Hypertension" (7 trials) and "Multiple Myeloma" (7 trials). Many other conditions were trialed in "Universitätsklinikum Erlangen" in a lesser frequency.

Most popular intervention types in "Universitätsklinikum Erlangen" are "Drug" (168 trials), "Device" (64 trials), "Other" (27 trials), "Biological" (25 trials) and "Procedure" (18 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (57 trials), "Spesolimab" (6 trials), "Guselkumab" (5 trials), "Capecitabine" (4 trials) and "Nintedanib" (4 trials). Other intervention names were less common.

The vast majority of trials in "Universitätsklinikum Erlangen" are 288 trials for "All" genders, 21 trials for "Female" genders and 8 trials for "Male" genders.

Currently, there are 112 active trials in "Universitätsklinikum Erlangen". 1 are not yet recruiting, 58 are recruiting, 51 are Active, not recruiting, and 2 are Enrolling by invitation. In total, there were 147 completed trials in Universitätsklinikum Erlangen, undefined suspended trials, and 32 terminated clinical trials to date.

Out of the total trials that were conducted in Universitätsklinikum Erlangen, 10 "Phase 1" clinical trials were conducted, 85 "Phase 2" clinical trials and 92 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 15 trials, and there were also 55 trials that are defined as “Not Applicable".

Universitätsklinikum Erlangen has several departments that took part in Clinical trials: "Department of Gynecology and Obstetrics, Erlangen University Hospital" - 12 trials, "Universitätsklinikum Erlangen, Neurologische klinik" - 9 trials, "Nephrology Department, University Hospital Erlangen" - 5 trials, "Universitätsklinikum Erlangen, Klinik für Kinder- und Jugendmedizin, Pädiatrische Onkologie / Hämatologie" - 2 trials, "Department of Anesthesiology, University Hospital Erlangen" - 2 trials, "University of Erlangen-Nurenberg, Division of Hematology/Oncology" - 2 trials, "Universitätsklinikum Erlangen; Medizinische Klinik 4; Nephrologie und Hypertensiologie" - 2 trials, "CRC Medical Department IV" - 2 trials